Janus kinase inhibitors efficacy for the treatment of adult atopic dermatitis in real clinical practice

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Atopic dermatitis is a common chronic dermatosis characterized by a wide variability of endotypes and phenotypes.

Approaches to the treatment of atopic dermatitis are currently undergoing significant changes, especially in patients with moderate and severe forms of atopic dermatitis. JAK inhibitors according to the results of numerous studies have shown their efficacy in the treatment of various immune-mediated dermatological diseases such as atopic dermatitis, vitiligo, focal alopecia and psoriasis, etc.

The article presents the experience of treating adult patients suffering from a severe form of atopic dermatitis with the selective JAK-1 inhibitor upadacitinib. The observations presented are of particular interest due to the fact that the patients were treated with upadacitinib monotherapy. It should be noted that the drug is highly effective against itching. No adverse events (including the development of infectious diseases, hematological disorders) were registered during dynamic observation (according to the results of laboratory studies).

Full Text

Restricted Access

About the authors

Evgeniya A. Shatokhina

Central State Medical Academy of Department of Presidential Affairs; Lomonosov Moscow State University, Medical Scientific and Educational Center

Author for correspondence.
Email: e.a.shatokhina@gmail.com
ORCID iD: 0000-0002-0238-6563
SPIN-code: 3827-0100
Scopus Author ID: 57189575975

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow; Moscow

Aleksandra S. Polonskaia

Central State Medical Academy of Department of Presidential Affairs

Email: dr.polonskaia@gmail.com
ORCID iD: 0000-0001-6888-4760
Russian Federation, Moscow

Anastasiya Yu. Syryseva

Central State Medical Academy of Department of Presidential Affairs

Email: syryseva.a@yandex.ru
ORCID iD: 0000-0001-9585-8373

ординатор кафедры

Russian Federation, Moscow

Anna V. Michenko

Central State Medical Academy of Department of Presidential Affairs; Lomonosov Moscow State University, Medical Scientific and Educational Center

Email: amichenko@mail.ru
ORCID iD: 0000-0002-2985-5729

MD, Cand. Sci. (Med), Assistant Professor

Russian Federation, Moscow; Moscow

Maksim N. Shatokhin

Russian Medical Academy of Continuous Professional Education

Email: m.n.shatokhin@gmail.com
ORCID iD: 0000-0002-1285-7357

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Larisa S. Kruglova

Central State Medical Academy of Department of Presidential Affairs

Email: kruglovals@mail.ru
ORCID iD: 0000-0002-5044-5265

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

References

  1. Murashkin NN, Namazova-Baranova LS, Opratin LA, et al. Biological therapy of moderate and severe forms of atopic dermatitis in childhood. Issues Modern Pediatrics. 2020;19(6):432–443. (In Russ). doi: 10.15690/vsp.v19i6.2145
  2. He H, Guttman-Yassky E. Jak inhibitors for atopic dermatitis: An update. Am J Clin Dermatol. 2019;20(2):181–192. doi: 10.1007/s40257-018-0413-2
  3. Salvati L, Cosmi L, Annunziato F. From emollients to biologicals: Targeting atopic dermatitis. Int J Mol Sci. 2021;22(19):10381. doi: 10.3390/ijms221910381
  4. Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Academy Dermatol. 2018; 78(3, Suppl 1):S53–S62. doi: 10.1016/j.jaad.2017.12.019
  5. Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;(10):2847. doi: 10.3389/fimmu.2019.02847
  6. Shaposhnikov AV, Komarkov IF, Lebedeva LA, Shidlovsky YV. The structure of the JAK/STAT signaling pathway and its relationship with the transcription apparatus. Molecular Biology. 2013;47(3):388. (In Russ). doi: 10.7868/S0026898413030130
  7. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038. doi: 10.1021/jm401490p
  8. Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744. doi: 10.1016/j.jaad.2016.12.005
  9. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity. 2012;36(4):515−528. doi: 10.1016/j.immuni.2012.03.016
  10. Basquiera AL, Soria NW, Ryser R, et al. Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology. 2009;14(6):323–330. doi: 10.1179/102453309X12473408860226
  11. Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012;2(7):591–597. doi: 10.1158/2159-8290.CD-12-0028
  12. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157–163. doi: 10.1038/nature10725
  13. Tsilifis C, Freeman AF, Gennery AR. STAT3 Hyper-IgE syndrome-an update and unanswered questions. J Clin Immunol. 2021;41(5):864–880. doi: 10.1007/s10875-021-01051-1
  14. Kim HO. Development of JAK inhibitors for the treatment of immune-mediated diseases: Kinase-targeted inhibitors and pseudokinase-targeted inhibitors. Arch Pharm Res. 2020;43(11): 1173–1186. doi: 10.1007/s12272-020-01282-7
  15. Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat. 2020;31(1):33–40. doi: 10.1080/09546634.2019.1577549
  16. Calabrese L, Chiricozzi A, De Simone C, et al. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis. Expert Opin Drug Metab Toxicol. 2022;18(5):347–355. doi: 10.1080/17425255.2022.2099835
  17. Tokura Y, Hayano S. Subtypes of atopic dermatitis: From phenotype to endotype. Allergol Int. 2022;71(1):14–24. doi: 10.1016/j.alit.2021.07.003
  18. Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis. Dermatol Ther. 2022;35(9):e15636. doi: 10.1111/dth.15636

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. JAK/STAT signaling path.

Download (981KB)
Indexing metadata
3. Fig. 2. Patient A., born in 1971, with severe atopic dermatitis in the acute stage: The dynamics of the skin process during therapy with upadacitinib.

Download (1MB)
Indexing metadata
4. Fig. 3. Patient О., born in 1989, with severe atopic dermatitis in the acute stage: Dynamics of the skin process during therapy with upadacitinib.

Download (3MB)
Indexing metadata
5. Fig. 4. Patient O., 7 months after the start of upadacitinib therapy.

Download (2MB)
Indexing metadata
6. Fig. 5. Patient A. Dynamics of diagnostic indices SCORAD and DLQI within 2 months during therapy with upadacitinib.

Download (499KB)
Indexing metadata
7. Fig. 6. Pation O. Dynamics of diagnostic indices SCORAD, EASI and DLQI within 7 months during therapy with upadacitinib.

Download (556KB)
Indexing metadata

Copyright © Pharmarus Print Media, 2023



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies